Zobrazeno 1 - 2
of 2
pro vyhledávání: ''
Autor:
Zita Borbényi, Suddhasatta Acharyya, Karen W.L. Yee, Je-Hwan Lee, Massimo Breccia, S. Ide, Árpád Illés, Alan Macwhannell, Carlos Graux, Miklos Egyed, Nancy Zhu, David Valcárcel, James D. Cavenagh, Reinhard Stauder, Huda Salman, Daniel J. DeAngelo, Mikkael A. Sekeres, M. Marker, Oliver G. Ottmann, G. Garcia-Manero, Lucien Gazi, Pierre Fenaux
Publikováno v:
Leukemia
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is
Autor:
V H J van der Velden, Inge Jedema, Renee M.Y. Barge, Bart A. Nijmeijer, Roelof Willemze, Jhf Falkenburg, J. J. M. Van Dongen
Publikováno v:
Leukemia, 18, 316-325. Nature Publishing Group
Multicenter phase II trials with Gemtuzumab Ozogamicin (GO/Mylotarg), consisting of a CD33 antibody linked to the cytotoxic drug calicheamicin, have shown a 30% overall response rate in relapsed acute myeloid leukemia patients. However, no clear corr